Clinical trial
A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease
NCT01331122 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease
- Lead sponsor
- Chelsea Therapeutics
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- April 30, 2012
- Completion date
- December 31, 2012
- Enrollment
- 0 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.